Mangrove Partners’s Guardant Health GH Stock Holding History

Mangrove Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,737	Closed	-$1.1M	–	504
2025 Q4	$1.1M	Buy	+10,737	New	+$961K	0.09%	88
2025 Q3	–	Sell	-15,664	Closed	-$815K	–	208
2025 Q2	$815K	Hold	15,664	–	–	0.09%	87
2025 Q1	$667K	Buy	+15,664	New	+$676K	0.07%	98
2024 Q4	–	Sell	-33,103	Closed	-$759K	–	174
2024 Q3	$759K	Buy	+33,103	New	+$937K	0.07%	123

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mangrove Partners's GH Position: Q1 2026 in Review

Mangrove Partners sold out of Guardant Health (GH) in Q1 2026, closing a stake of 10,737 shares — an estimated $1.1M sold.

Mangrove Partners first reported a position in GH in Q3 2024 and held it in 4 quarters. The position peaked at $1.1M in Q4 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Mangrove Partners reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
Mangrove Partners sold 10,737 Guardant Health shares in Q1 2026, an estimated $1.1M.
Mangrove Partners first reported a position in Guardant Health in Q3 2024 and held it in 4 quarters.
Mangrove Partners's Guardant Health position peaked at $1.1M in Q4 2025.
481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.